eligible patients were challenged with antigen 27 minutes after dosing. To assess duration of action, patients were challenged with allergen 16 hours after dosing. The percentage of eyes with zero itching in both studies was assessed at 3 minutes post allergen challenge. Results: The percentage of eyes with zero itch at the 3 minutes timepoint after the onset of action allergen challenge was 60.0% for OLO-treated eyes compared with 5.9% for vehicle-treated eyes (P , .0001, OLO vs vehicle). The percentage of eyes with zero itch at 3 minutes post allergen challenge following the 16-hour dosing was 59.8% for OLO-treated eyes compared with 22.0% for vehicle-treated eyes (P , .0001, OLO vs vehicle). Conclusions: In bilateral CAC studies, ocular itching was prevented in a higher percentage (P , .0001) of eyes treated with 0.2% olopatadine hydrochloride ophthalmic solution when compared with vehicle as early as 30 minutes and for at least 16 hours post dosing. Results: A total of 427 patients (mean age ¼ 49.8 years) were patch tested, 82% were female, 54% reported an atopic history (history of asthma, atopic dermatitis, allergic rhinitis or food allergy), 30% were tested with TT, 60% with NACD panel, 30% with cosmetic series, 15% with corticosteroid series and 35% with personal products. The 5 most common positive PT allergens were nickel sulfate, fragrance mix I, P-phenylenediamine, thimerosal and cobalt chloride. The most common dermatitis sites were eyelid/periorbital (31%), facial (25%) and trunk (21%). 56.9% of patients were positive to at least one TT allergen. 25.6% of patients were positive to both a TT and a supplemental allergen (these patients would have been "partially evaluated" with TT allergens alone as they are positive to at least 1 TT allergen and 1 supplemental allergen). 12.5% of patients were negative to a TT allergen and positive to at least 1 supplemental allergen only (these patients would have been "missed" as they are negative to all TT allergens, but positive to at least 1 supplemental allergen). Conclusions: Nickel remains the most common allergen. When evaluating patients with CD, testing with TT allergens alone would miss 12.5% of patients while 25.6% of patients would be only partially evaluated. As half of our patients were positive to at least 1 TT allergen, the TT remains an adequate screening tool but a more comprehensive panel may be needed to fully evaluate contact dermatitis.
New York Allergy and Asthma, Weill Cornell Medical College, New York, NY; 4 Medicine, Winthrop University Hospital, Mineola, NY. Background: Contact Dermatitis (CD) is a frequently encountered skin disease by allergists and dermatologists that results from contact with external allergens. Patch Testing (PT) remains the gold standard in the diagnosis of allergic CD. Studies evaluating PT from allergy practices are lacking. Methods: A multi-center, retrospective chart review of PT within the last 5 years at allergy practices in 3 institutions. We report PT results using allergens in the Thin-Layer Rapid-Use Epicutaneous Test (TT) and additional supplemental allergens [North American Contact Dermatitis (NACD) Panel, Dormer Cosmetic Panel, hairdresser's panel, corticosteroid panel and personal products]. Additionally, patient characteristics including age, gender, occupation, dermatitis site, history of atopic disease and final diagnosis were also obtained. Results: A total of 427 patients (mean age ¼ 49.8 years) were patch tested, 82% were female, 54% reported an atopic history (history of asthma, atopic dermatitis, allergic rhinitis or food allergy), 30% were tested with TT, 60% with NACD panel, 30% with cosmetic series, 15% with corticosteroid series and 35% with personal products. The 5 most common positive PT allergens were nickel sulfate, fragrance mix I, P-phenylenediamine, thimerosal and cobalt chloride. The most common dermatitis sites were eyelid/periorbital (31%), facial (25%) and trunk (21%). 56.9% of patients were positive to at least one TT allergen. 25.6% of patients were positive to both a TT and a supplemental allergen (these patients would have been "partially evaluated" with TT allergens alone as they are positive to at least 1 TT allergen and 1 supplemental allergen). 12.5% of patients were negative to a TT allergen and positive to at least 1 supplemental allergen only (these patients would have been "missed" as they are negative to all TT allergens, but positive to at least 1 supplemental allergen). Conclusions: Nickel remains the most common allergen. When evaluating patients with CD, testing with TT allergens alone would miss 12.5% of patients while 25.6% of patients would be only partially evaluated. As half of our patients were positive to at least 1 TT allergen, the TT remains an adequate screening tool but a more comprehensive panel may be needed to fully evaluate contact dermatitis.
Contact Allergy to Medicaments in Consecutively Patch-tested Patients in Uruguay
Valeria Pomies, MD, and Iris Ale, MD. Allergy Unit and Department of Dermatology, University Hospital, Republic University of Uruguay, Montevideo, Uruguay. Background: Allergic contact dermatitis (ACD) to topical medicaments is common. Medicaments are responsible for approximately 30% of all cases of ACD. The most common drugs associated with ACD include topically applied antibiotics, antiseptics, antihistamines, anesthetics, nonsteroidal antiinflammatory drugs, and corticosteroids.Certain body areas are particularly susceptible (ie, genital and perianal areas, ears, eyes, face and lower legs)Predisposing factors are: occlusion (skin folds, use of bandages), application in damaged skin (stasis dermatitis & leg ulcers, and other chronic dermatitis) and long-lasting use of multiple medicamentsThe aim of our study was to study the prevalence of ACD to topical medicaments in patients with suspected ACD attending the Unit of Allergy at the University Hospital in Montevideo. Methods: 1175 consecutive patients; 781 F (63%) 394 M (37%) with suspected ACD were patch tested with the standard series and the topical medicament series, as well as other allergens according to the clinical situation. Results: The most frequent allergens were: Neomycin (7.1%), Thiomersal (3.8%), Benzocaine (1.9%), Bacitracin (1.9%), Propolis (1.5%), Gentamycin (1.2%), Tixocortol (1.1%) and Budesonide 24 (0.8%). Conclusions: Contact allergy to topical medicaments is common in patients studied by a suspected ACD in Uruguay. In these cases the topical medicaments that the patient is using should be included when patch testing.
Evaluation of Allergen Sensitivity in Patients with Contact Dermatitis in Antalya

